Laura Annaratone
Overview
Explore the profile of Laura Annaratone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berrino E, Annaratone L, Bellomo S, Ferrero G, Gagliardi A, Bragoni A, et al.
Genome Med
. 2022 Aug;
14(1):98.
PMID: 36038884
Background: The "HER2-low" nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated....
2.
Berrino E, Annaratone L, Detillo P, Grassini D, Bragoni A, Sapino A, et al.
Pathobiology
. 2022 Jul;
90(3):155-165.
PMID: 35858535
Introduction: Optimization of pre-analytic procedures and tissue processing is a basic requirement for reliable and reproducible data to be obtained. Tissue fixation in formalin represents the extensively favored method for...
3.
Grassini D, Cascardi E, Sarotto I, Annaratone L, Sapino A, Berrino E, et al.
Pathobiology
. 2022 May;
89(5):278-296.
PMID: 35500561
The biomarker human epidermal growth factor receptor-2 (HER2) has represented the best example of successful targeted therapy in breast cancer patients. Based on the concept of "oncogene addiction," we have...
4.
Giunta E, Annaratone L, Bollito E, Porpiglia F, Cereda M, Banna G, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638258
Prostate cancer (PCa) therapy has been recently revolutionized by the approval of new therapeutic agents in the metastatic setting. However, the optimal therapeutic strategy in such patients should be individualized...
5.
Berrino E, Bragoni A, Annaratone L, Fenocchio E, Carnevale-Schianca F, Garetto L, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34282766
Agnostic biomarkers such as gene fusions allow to address cancer patients to targeted therapies; however, the low prevalence of these alterations across common malignancies poses challenges and needs a feasible...
6.
Annaratone L, De Palma G, Bonizzi G, Sapino A, Botti G, Berrino E, et al.
Virchows Arch
. 2021 Jul;
479(2):233-246.
PMID: 34255145
The term "biobanking" is often misapplied to any collection of human biological materials (biospecimens) regardless of requirements related to ethical and legal issues or the standardization of different processes involved...
7.
Ruiu R, Barutello G, Arigoni M, Riccardo F, Conti L, Peppino G, et al.
Cancers (Basel)
. 2021 Mar;
13(4).
PMID: 33672732
Triple-negative breast cancer (TNBC) is insensitive to endocrine and Her2-directed therapies, making the development of TNBC-targeted therapies an unmet medical need. Since patients with TNBC frequently show a quicker relapse...
8.
Metovic J, Vignale C, Annaratone L, Osella-Abate S, Maletta F, Rapa I, et al.
J Clin Endocrinol Metab
. 2020 Sep;
105(12).
PMID: 32936917
Background: Poorly differentiated thyroid cancer (PDTC) is a rare, follicular cell-derived neoplasm with an unfavorable prognosis. The oncocytic variant of PDTC may be associated with even more adverse outcome than...
9.
Elhasnaoui J, Miano V, Ferrero G, Doria E, Leon A, Fabricio A, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32503257
is a cancer-related long noncoding RNA with higher expression levels in Luminal A, B, and HER2-positive Breast Carcinoma (BC), where its expression is strongly dependent on Estrogen Receptor Alpha (ERα)....
10.
Metovic J, Annaratone L, Linari A, Osella-Abate S, Musuraca C, Veneziano F, et al.
Cancer Immunol Immunother
. 2020 May;
69(9):1905-1916.
PMID: 32377818
Giant cell tumor of bone (GCTB) is a locally aggressive and rarely metastatic tumor, with a relatively unpredictable clinical course. A retrospective series of 46 GCTB and a control group...